Monitor for any takedown notices or Form 4 filings from selling stockholders indicating actual share sales. The overhang is real but the company is not raising capital; the pace of resales will determine market impact.
EQ drugs
EQ drug pipeline →Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Equillium's S-3 registration statement (File No. 333-300003) became effective on November 19, 2026. The shelf registers 35,087,717 shares of common stock for resale by selling stockholders from an October 2026 private placement; the company will not receive any proceeds. This creates a potential overhang of shares that can be sold into the market at any time, but does not represent a new capital raise by the company.
Key Facts
- Effectiveness date: November 19, 2026
- S-3 File No. 333-300003 registers 35,087,717 shares for resale by selling stockholders
- Shares originated from a private placement that closed on October 26, 2026
- Equillium will not receive any proceeds from the resale
- Filing is a contractual obligation under a Registration Rights Agreement
Financial Impact
35,087,717 shares registered for resale; company receives no proceeds
Risk Factors
- Selling stockholders may sell shares into the market, creating downward price pressure
- The registered shares represent a significant portion of outstanding shares relative to the $100M market cap
- No lock-up or resale restrictions beyond standard securities law compliance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-003588 |
| Document: 9999999995-26-003588-index.html | 9999999995-26-003588 |
| Document: 9999999995-26-003588.txt | 9999999995-26-003588 |
Track record
20 reports on EQ
2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 20, 20262d ago EFFECT Neutral 4/10 Viewing Entry $1.12 Now $1.06 −5.36% settles Nov 23
- Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
- Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
- Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
- Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
- Nov 4, 202617d ago SC 13G/A Neutral 2/10 Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
- Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
- Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
- Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers